 | | Vol. 7.09 – 21 March, 2022 |
| |
|
|
| Scientists fabricated a micro- to nanoscale network assembly consisting of copper ion and epigallocatechin gallate via π–π interactions, metal coordination, and oxidative polymerization.
[ACS Nano] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers developed an implantation-on-a-chip that was capable of reconstructing the 3D structural organization of the maternal-fetal interface to model the invasion of specialized fetal extravillous trophoblasts into the maternal uterus.
[Nature Communications] |
|
|
|
| Pannexin-1 on endothelial cells acted as a conduit for ATP release that stimulated macrophage activation via P2X7 receptors and mitochondrial DNA release to increase IL-1β and HMGB1 secretion.
[Nature Communications] |
|
|
|
| Using a streptozotocin-induced diabetic wound healing mouse model, investigators showed that, compared with miR-scrambled-modulated small extracellular vesicles (sEVs), topical administration of miR-425-5p-modulated sEVs significantly enhanced wound healing.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| VEGF/nerve growth factor (NGF)-nanoparticles promoted VEGF and NGF co-expression simultaneously, eliminated excessive H2O2, strengthened reactions between SH-SY5Ys and HUVECs, and finally enhanced migration, tube formation, proliferation and H2O2 damage resistance of HUVECs.
[Journal of Nanobiotechnology] |
|
|
|
| Scientists investigated how tumor endothelial cells influenced tumor growth and immune responses of hepatocellular carcinoma focusing on CD8+ T cell infiltration and exhaustion.
[Cancer Science] |
|
|
|
| The authors tested the effects of platelet-derived growth factor-BB (PDGF-BB) on primary human brain pericytes in vitro to define pathways related to blood-brain barrier function.
[Communications Biology] |
|
|
|
| Researchers reported that soluble Robo4 was the product of constitutive ectodomain shedding of endothelial cell surface Robo4 by disintegrin metalloproteinases ADAM10 and ADAM17 and acted to inhibit angiogenic Slit3 signaling.
[Scientific Reports] |
|
|
|
| Investigators examined blood–brain barrier disruption, by assessing brain-derived neurotropic factor, neuron-specific enolase levels, and gut-blood barrier disruption by trimethylamine N-oxide in chronic kidney disease patients.
[Scientific Reports] |
|
|
|
| Scientists evaluated the impact of morphine exposure at three different concentrations for 24 hours and 48 hours on primary human brain microvascular endothelial cells.
[Scientific Reports] |
|
|
|
| The authors identified cell-specific transcriptional signatures associated with age and heart failure and reveal the emergence of disease-associated cell states. Cardiomyocytes converged toward common disease-associated cell states, whereas fibroblasts and myeloid cells underwent dramatic diversification.
[Nature Cardiovascular Research] |
|
|
|
|
| Scientists discuss emerging evidence suggesting a tissue-specific and vessel type-specific immunomodulatory role for distinct subtypes of endothelial cells, collectively referred to as ‘immunomodulatory endothelial cells’.
[Nature Reviews Immunology] |
|
|
|
| The authors discuss the biology and roles of pericytes, their markers for identification, and cell differentiation capacity with a focus on the potential application in the treatment of spinal cord injury and bone diseases in orthopedics.
[Bone Research] |
|
|
|
|
| Apellis Pharmaceuticals, Inc. announced longer-term data from the Phase III DERBY and OAKS studies, which showed that intravitreal pegcetacoplan continued to reduce GA lesion growth and demonstrated a favorable safety profile at month 18 for the treatment of GA secondary to age-related macular degeneration.
[Apellis Pharmaceuticals, Inc.] |
|
|
|
| Ocuphire Pharma, Inc. announced that it has completed enrollment of 103 diabetic patients with moderately severe-to-severe non-proliferative diabetic retinopathy or mild proliferative diabetic retinopathy in ZETA-1, a Phase IIb trial evaluating the efficacy and safety of APX3330 for the treatment of diabetic retinopathy.
[Ocuphire Pharma, Inc.] |
|
|
|
|
| May 5 – 8, 2022
Boston, Massachusetts, United States |
|
|
|
|
|
| | Thorax Institute – Nantes, France |
|
|
|
| Babraham Institute – Cambridgeshire, England, United Kingdom |
|
|
|
| | Johns Hopkins School of Medicine – Saint Petersburg, Florida, United States |
|
|
|
| | The University of Tennessee Health Science Center – Memphis, Tennessee, United States |
|
|
|
| | Yale University – New Haven, Connecticut, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
